GlassScriptPhysician profile
Ragan King
NPI 1164249223
$1,815.88
in general payments reported to CMS, 2019-2025
18 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $300 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $459.78 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $416.77 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $369.78 | 2024-2025 | Wegovy, Ozempic |
| Exact Sciences Corporation | $114.20 | 2024-2025 | Cologuard Collection Kit |
| Corium, LLC | $72.34 | 2025 | Azstarys |
| Antares Pharma, INC. | $66.74 | 2024-2025 | Xyosted |
| Pfizer INC. | $64.55 | 2025 | |
| Abbvie INC. | $36.55 | 2025 | Ubrelvy, Qulipta, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $35.69 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.96 | 2025 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.40 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.82 | 2025 | Pyrukynd |
| Amneal Pharmaceuticals LLC | $19.82 | 2025 | Crexont |
| Merck Sharp & Dohme LLC | $18.33 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Kowa Pharmaceuticals America, INC. | $17.55 | 2024 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.21 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $14.66 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $13.73 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ragan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.